<DOC>
	<DOCNO>NCT00802022</DOCNO>
	<brief_summary>Rationale : Diabetic neuropathy one common complication Diabetes Mellitis ( DM ) . Pain common symptom diabetic neuropathy , affect 11-34 % patient suffer form DM . The current available medication often provide insufficient pain relief and/or unacceptable side effect . Spinal cord stimulation ( SCS ) use 30 year treat neuropathic pain . Various small clinical study show beneficial effect SCS pain PDP . Objective : This study preparation RCT investigate whether SCS good indication patient suffer pain moderate-to-severe PDP low limb . The main objective study whether SCS lead sufficient pain relief obtain insight work mechanism SCS . The hypothesis effect SCS effective patient without major sensory deficit . Furthermore , practical feasibility test procedure describe study protocol examine , include questionnaire fill patient . Also , technical feasibility SCS investigate . Besides feasibility , possibility predict successful pain relief SCS classifying patient accord Michigan Diabetic Neuropathy Score assess . Furthermore , possible predictor successful pain relief SCS define . Study design : study pilot study preparation RCT investigate effect spinal cord stimulation pain moderate-to-severe PDP patient . Study population : patient suffer moderate-to-severe PDP low limb diagnose clinical symptom support Michigan Diabetic Neuropathy Score . Intervention : patient receive 2 week trial stimulation best ( drug ) treatment usual . Main study parameters/endpoints : Main study parameter pain score measure numeric rating scale ( NRS ) accord Jensen Patient Global Impression Change pain measure 7-point Likert scale . Nature extent burden risk associate participation , benefit group relatedness : SCS related risk include : lead migration ( 14 % ) , lead breakage ( 7 % ) , implant pulse generator migration ( 1 % ) , loss therapeutic effect , lose unpleasant paresthesia ( 12 % ) , infection wind breakdown ( 10 % ) , Pain IPG incision site ( 12 % ) , IPG pocket fluid collection ( 5 % ) .</brief_summary>
	<brief_title>Effect Spinal Cord Stimulation Painful Diabetic Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Moderatetosevere PDP low limbs The pain intend treat present 12 month Previous treatment unsuccessful ( insufficient pain relief and/or unacceptable sideeffects ) drug follow drug category : Amitriptyline tricyclic antidepressant and/or Pregabalin ( Lyrica ) , Gabapentin ( Neurontin ) Carbamazepine and/or Duloxetine ( Cymbalta ) and/or Tramadol strong opioids Patients treat 3 drug mention drug category follow treatment algorithm painful diabetic polyneuropathy accord Jensen . Each drug try 3 week dose raise . By insufficient pain relief and/or unacceptable sideeffects , drug treatment stop . Patients reach steady state medication use allow change use medication study . Mean pain intensity 5 high measure numeric rating scale ( NRS ) , score 3 time per day 4 day accord Jensen . Patients age 18 75 year . The patient neuromodulation therapy month intake The patient ever neuromodulation Neuropathic pain prevalent upper limb ( NRS 3 ) Neuropathy chronic pain origin diabetes mellitus ( NRS 3 ) Addiction : drug , alcohol ( 5E/day ) and/or medication Drugs : cocaine , heroine , marihuana , Alcohol : wine , beer , liquor . Medication : benzodiazepine , morphine receptor agonist . Insufficient cooperation patient ( little motivation , understand communication ) Blood clot disorder Immune deficiency ( HIVpositive , corticosteroid dose equivalent prednisolone 10 mg , immunosuppressive , etc . ) Peripheral vascular disease , palpable peripheral pulsation foot ( inclusion possible pulsation absent , ankle/brachial index 0.7 1.2 foot ) Active foot ulceration Life expectancy shorter 1 year Pacemaker Local infection skin disorder site incision Psychiatric disorder Pregnancy Severe cardiac pulmonary failure ( NYHA classification II high ) Unstable blood glucose control ( change HbA1c 1,0 % ( absolute value ) three month prior inclusion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>diabetic neuropathy</keyword>
	<keyword>electric stimulation therapy</keyword>
</DOC>